Lumito (LUMITO) Q2 2025 earnings summary

Executive summary

• No revenue generated in Q2 2025; net loss increased to -11,275 TSEK compared to -8,132 TSEK year-over-year.

• Operating costs rose due to higher depreciation from capitalized R&D and patents.

• Strategic focus on commercializing innovative tissue analysis technology, with strengthened scientific advisory and new partnerships.

• Team and leadership changes, including appointment of a new CFO and expansion of the Scientific Advisory Board.

Financial highlights

• Net loss for Q2 2025 was -11,275 TSEK, up from -8,132 TSEK in Q2 2024.

• Operating loss for Q2 2025 was -10,826 TSEK, compared to -7,243 TSEK year-over-year.

• Cash flow from operations in Q2 2025 was -7,374 TSEK, an improvement from -9,067 TSEK in Q2 2024.

• Cash and cash equivalents at period end were 7,178 TSEK, down from 32,326 TSEK a year earlier.

• Equity at period end was 69,714 TSEK, compared to 107,447 TSEK year-over-year.

Outlook and guidance

• Focus remains on commercializing the SCIZYS platform and expanding market presence.

• Strategic partnerships and CRO collaborations are expected to drive growth.

• Next financial report scheduled for October 30, 2025.